Literature DB >> 11696744

The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment.

A Zisman1, D Leibovici, J Kleinmann, A Cooper, Y Siegel, A Lindner.   

Abstract

PURPOSE: We studied the possible association of transrectal ultrasound guided prostate biopsy with voiding impairment.
MATERIALS AND METHODS: A total of 211 consecutive patients were prospectively enrolled. International Prostate Symptom Score (I-PSS), subjective voiding complaints and retention were recorded in 3 personal interviews before biopsy, and on postoperative days 7 and 30.
RESULTS: Of the 204 patients who voided via the urethra at biopsy 52 (25%) reported subjective voiding impairment on postoperative day 7, including 12% who defined difficult voiding as mild-1 to 2 points on a 0 to 5 scale, 8% as moderate-3/5 and 5% as severe-4 to 5/5. In 5 of the latter cases (2.5%) acute urinary retention necessitated urethral catheter insertion. Transition zone volume, which was 42 ml. or larger in all patients in urinary retention, was the only independent variable associated with patient report of subjective difficult voiding and acute urinary retention during week 1 after biopsy (p = 0.03). Baseline I-PSS greater than 20 points indicated a risk of an acute transient increase in I-PSS on postoperative day 7.
CONCLUSIONS: Transient voiding impairment may be precipitated by ultrasound guided prostate biopsy. To decrease this morbidity appropriate evaluation and possible treatment for bladder outlet obstruction are justified in patients with a larger transition zone and in those with preoperative baseline I-PSS greater than 20 points.

Entities:  

Mesh:

Year:  2001        PMID: 11696744

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Prevention and treatment of biopsy-related complications.

Authors:  Ramgopal Satyanarayana; Dipen Parekh
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

2.  The preventive effect of tamsulosin on voiding dysfunction after prostate biopsy: a prospective, open-label, observational study.

Authors:  Seung Jun Chung; Seung Il Jung; Ji Won Ryu; Eu Chang Hwang; Dong Deuk Kwon; Kwangsung Park; Jin Woong Kim
Journal:  Int Urol Nephrol       Date:  2015-03-27       Impact factor: 2.370

Review 3.  The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety.

Authors:  Alexander P Glaser; Kristian Novakovic; Brian T Helfand
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

4.  Is there any priority between the alpha blockers on voiding functions after transrectal ultrasound guided prostate biopsy?

Authors:  Ozan Efesoy; Barış Saylam; Mesut Tek; Murat Bozlu; Erdem Akbay
Journal:  Turk J Urol       Date:  2021-03-01

Review 5.  Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis.

Authors:  Dechao Feng; Cai Tang; Shengzhuo Liu; Yubo Yang; Ping Han; Wuran Wei
Journal:  Int J Impot Res       Date:  2020-10-24       Impact factor: 2.896

6.  The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy.

Authors:  Hanan Goldberg; Faizan K Mohsin; Thenappan Chandrasekar; Christopher J D Wallis; Zachary Klaassen; Ardalan E Ahmad; Refik Saskin; Miran Kenk; Olli Saarela; Girish S Kulkarni; Shabbir M H Alibhai; Neil Fleshner
Journal:  Can Urol Assoc J       Date:  2022-05       Impact factor: 2.052

7.  Short-term prophylaxis with ciprofloxacin in extended 16-core prostate biopsy.

Authors:  Renato Caretta Chambó; Fabio Hissachi Tsuji; Hamilton Akihissa Yamamoto; Carlos Marcio Nobrega de Jesus
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

8.  Intrarectal ice application prior to transrectal prostate biopsy: a prospective randomised trial accessing pain and collateral effects.

Authors:  Baris Caliskan; Nazim Mutlu
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.